In the special article “Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology,” by Rae-Grant et al.,1 there are errors in figures 1 and 3. In figure 1, a superscript “a” is missing from “Ocrelizumab” to indicate the comparator intervention (interferon-β-1a 44 μg 3 times per week subcutaneously); in figure 3, a superscript “b” is missing from “Ocrelizumab,” also to indicate the comparator intervention (interferon-β-1a). Additionally, in the table “Efficacy of disease modifying therapies (DMTs) for reducing the annualized relapse rate (ARR) and risk of relapse at 2 years,” there should not be an entry for “very low” confidence for azathioprine under “Reduction of the ARR.” The entry for very low confidence for azathioprine under “Reduction of risk of relapse at 2 y” appears correctly. The authors regret the errors.
- © 2019 American Academy of Neurology
Reference
- 1.↵
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis
Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS
Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis